Drug combo shows promise for Hard-to-Treat blood cancer
NCT ID NCT03946878
First seen Nov 17, 2025 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This phase II trial is testing whether combining two oral drugs, venetoclax and acalabrutinib, can help people with mantle cell lymphoma that has come back or not responded to prior treatment. The study includes 32 participants and aims to see how many achieve a complete response. The drugs work by blocking survival signals in cancer cells, potentially killing more of them together than alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax and acalabrutinib (two oral drugs)
What this could lead to
If successful, this combination could offer a new treatment option for patients with mantle cell lymphoma that has stopped responding to other therapies.
What could go wrong
This is a small, early-phase trial with only 32 participants. The results may not apply to all patients, and side effects or lack of lasting benefit are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.